Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of $77.27M (cash outflow) rose 121.6% year over year, ahead of the +52.3% change in trailing-twelve-month free cash flow. Sequentially, it rose 77.5% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +121.6% holds above the trailing-twelve-month pace of +52.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (143.82M) USD
- Year-over-year change
- -30.3%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (143.82M) | -30.3% |
| FY2024 | 2024-12-31 | (110.34M) | -12.9% |
| FY2023 | 2023-12-31 | (97.69M) | -67.9% |
| FY2022 | 2022-12-31 | (58.18M) | -70.2% |
| FY2021 | 2021-12-31 | (34.18M) | — |
Free Cash Flow vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 free cash flow of $202.02M is the 3rd largest of the 10 companies compared; the peer median is $131.64M.
- Its year-over-year change of +52.3% is the 5th highest of 10, against a peer median of +50.2%.
- Over three fiscal years its annual growth of +35.2% compares with a peer median of +13.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $499.22M | +37.9% | +37.2% | — | |
| LTM Jun 2026 | $332.56M | -148.8% | — | 33.0% | |
| LTM Sep 2026 | $202.02M | +52.3% | +35.2% | — | |
| LTM Mar 2026 | $172.86M | +61.1% | +16.0% | — | |
| LTM Mar 2026 | $147.7M | -313.4% | — | 460.4% | |
| LTM Mar 2026 | $131.64M | +126.9% | +10.3% | 2294.2% | |
| LTM Mar 2026 | $131.32M | +50.2% | +60.0% | — | |
| LTM Mar 2026 | $113.96M | +141.6% | — | — | |
| LTM Mar 2026 | $106.14M | +115.2% | -4.9% | 4.9% | |
| LTM Mar 2026 | $77.27M | -7.3% | +9.1% | — | |
| Peer median (excluding EWTX) | $131.64M | +50.2% | +13.1% | 246.7% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| Deferred Income Tax | (2.29M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.4M | 10.92M | 17.56M | 24.71M | 34.75M |
| Change in Working Capital | 4.63M | 4.09M | (1.56M) | 10.33M | (5.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.65M | 47K | (92K) | 1.74M | 272K |
| Other Working Capital | 1.98M | 4.04M | (1.47M) | 8.59M | (5.65M) |
| Other Non-Cash Items | 2.29M | (543K) | (9.52M) | (12.55M) | (7.67M) |
| Operating Cash Flow | (33.51M) | (52.64M) | (91.95M) | (109.03M) | (143.82M) |
| Capital Expenditures | (668K) | (5.55M) | (5.75M) | (1.31M) | (256K) |
| Acquisitions (Net) | 241.56K | 65.03K | 0 | 0 | 0 |
| Purchases of Investments | (288.2M) | (292.39M) | (255.87M) | (477.06M) | (527.23M) |
| Sales of Investments | 46.64M | 227.36M | 364.5M | 293.71M | 494.69M |
| Other Investing Activities | (241.56K) | (65.03K) | 0 | 0 | 0 |
| Investing Cash Flow | (242.23M) | (70.58M) | 102.89M | (184.66M) | (32.79M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 186.15M | 129.17M | 52.62M | 239.15M | 196.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 236K | 474K | 548K | 10.11M | 0 |
| Financing Cash Flow | 186.38M | 129.64M | 53.17M | 249.25M | 196.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (89.35M) | 6.43M | 64.1M | (44.43M) | 19.48M |
| Free Cash Flow | (34.18M) | (58.18M) | (97.69M) | (110.34M) | (143.82M) |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.